This topic contains a solution. Click here to go to the answer

Author Question: A patient has been administered heparin to prevent thromboembolism development status postmyocardial ... (Read 74 times)

brutforce

  • Hero Member
  • *****
  • Posts: 540
A patient has been administered heparin to prevent thromboembolism development status postmyocardial infarction. The patient develops heparin-induced thrombocytopenia. Which of the following medications will be administered?
 
  A) Argatroban (Acova)
  B) Vitamin K
  C) Calcium gluconate
  D) Aminocaproic acid (Amicar)

Question 2

A patient with diabetes mellitus is prescribed captopril (Capoten) to treat hypertension. What electrolyte imbalance might the patient be prone to develop?
 
  A) Hyperkalemia
  B) Hypokalemia
  C) Hypernatremia
  D) Hypermagnesemia



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

mfedorka

  • Sr. Member
  • ****
  • Posts: 324
Answer to Question 1

A

Answer to Question 2

A




brutforce

  • Member
  • Posts: 540
Reply 2 on: Jul 23, 2018
Thanks for the timely response, appreciate it


helenmarkerine

  • Member
  • Posts: 324
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

Did you know?

Blood in the urine can be a sign of a kidney stone, glomerulonephritis, or other kidney problems.

Did you know?

Human neurons are so small that they require a microscope in order to be seen. However, some neurons can be up to 3 feet long, such as those that extend from the spinal cord to the toes.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

For a complete list of videos, visit our video library